What Are the Signs of Ozempic Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Targeted Pharmacovigilance

If you or a loved one is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that drug-induced gastrointestinal motility disorders, while rare, require careful clinical attention. This page covers the symptoms, FDA warning, and monitoring strategies for Ozempic-associated gastroparesis.

Ozempic and Gastroparesis: A Bridge from Pharmacology to Clinical Risk

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, is a serious gastrointestinal disorder that has been associated with GLP-1 receptor agonists, including Ozempic. This section examines the clinical presentation and diagnosis of gastroparesis, the pharmacology of Ozempic and its reported adverse effects, mechanistic pathways linking the drug to gastroparesis, and risk considerations including the adequacy of warnings, causation for affected patients, and the timeline between exposure and documented harm.

Clinical Evidence and Mechanistic Pathways

Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to malnutrition, weight loss, and impaired quality of life. In the context of Ozempic use, the drug's mechanism of action—delaying gastric emptying as part of its glucose-lowering effect—is directly relevant to gastroparesis pathophysiology. GLP-1 receptor agonists slow gastric motility, which can exacerbate or unmask underlying gastroparesis in susceptible individuals. The prescribing information for Ozempic reports that gastrointestinal adverse reactions occurred more frequently among patients receiving the drug compared to placebo. In a pool of placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which aligns with the known pharmacodynamic effect of delayed gastric emptying.

Risk Context and Warning Adequacy

Mechanistically, Ozempic activates GLP-1 receptors in the gastrointestinal tract, leading to inhibition of gastric motility and secretion. This effect is intended to reduce postprandial glucose excursions but can result in prolonged gastric retention. In patients with pre-existing gastroparesis or those with risk factors such as diabetes (which itself can cause autonomic neuropathy and gastroparesis), the drug may exacerbate symptoms. The prescribing information lists pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the common gastrointestinal adverse reactions—nausea, vomiting, abdominal pain, and constipation—are overlapping symptoms of gastroparesis, and the drug's effect on gastric emptying is a plausible mechanistic pathway. Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions in the "Adverse Reactions" section and notes that these reactions are most common during dose escalation. However, there is no specific warning for gastroparesis as a distinct adverse event. This may be insufficient for patients and clinicians to recognize the potential for the drug to cause or worsen gastroparesis, particularly in individuals with diabetes who are already at increased risk for this condition. The FDA has received adverse event reports linking GLP-1 receptor agonists to gastroparesis, and in 2023, the agency updated the labeling for these drugs to include a warning about ileus, a related condition. Nonetheless, the absence of a specific gastroparesis warning may leave some patients unaware of the risk.

Causation and Timeline Considerations

For affected patients, causation considerations involve establishing a temporal relationship between Ozempic initiation and the onset or worsening of gastroparesis symptoms. The timeline between exposure and documented harm can vary. In clinical trials, gastrointestinal adverse reactions occurred most frequently during dose escalation, suggesting that symptoms may appear within weeks of starting treatment or increasing the dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, delayed onset is also possible, as chronic use may lead to cumulative effects on gastric motility. Patients who develop persistent nausea, vomiting, or abdominal pain after starting Ozempic should be evaluated for gastroparesis, and discontinuation of the drug may lead to symptom improvement. The prescribing information notes that gastrointestinal adverse reactions led to discontinuation in 3.1% to 3.8% of patients, indicating that some individuals experience intolerable symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible link to gastroparesis causation. Current warnings in the prescribing information do not explicitly address gastroparesis, which may represent a gap in risk communication. Patients who experience persistent gastrointestinal symptoms after starting Ozempic should be evaluated for gastroparesis, and clinicians should consider the drug's role in symptom development. Further research is needed to clarify the incidence of gastroparesis in Ozempic users and to optimize risk mitigation strategies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to malnutrition, weight loss, and impaired quality of life.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that delays gastric emptying as part of its glucose-lowering effect. This mechanism can exacerbate or unmask underlying gastroparesis in susceptible individuals. Clinical trials show a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which are consistent with gastroparesis. However, the prescribing information does not explicitly list gastroparesis as a separate warning, though the FDA has received adverse event reports linking GLP-1 receptor agonists to gastroparesis and updated labeling to include a warning about ileus.

What are the symptoms of Ozempic-related gastroparesis?

Symptoms include persistent nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. These symptoms overlap with common gastrointestinal adverse reactions reported in Ozempic clinical trials, which occurred in up to 36.4% of patients. Symptoms often appear during dose escalation but can also develop after chronic use.

How long after starting Ozempic can gastroparesis develop?

Gastrointestinal adverse reactions most frequently occur during dose escalation, suggesting symptoms may appear within weeks of starting treatment or increasing the dose. However, delayed onset is possible with chronic use due to cumulative effects on gastric motility. Patients experiencing persistent symptoms should be evaluated for gastroparesis.

What should I do if I experience gastroparesis symptoms while taking Ozempic?

If you experience persistent nausea, vomiting, abdominal pain, or other symptoms of gastroparesis after starting Ozempic, consult your healthcare provider. They may evaluate you for gastroparesis and consider discontinuing the drug, as symptoms may improve upon cessation. The prescribing information notes that gastrointestinal adverse reactions led to discontinuation in 3.1% to 3.8% of patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.